Literature DB >> 17151807

The effect of oral alpha-galactosidase on intestinal gas production and gas-related symptoms.

Michele Di Stefano1, Emanuela Miceli, Samantha Gotti, Antonio Missanelli, Samanta Mazzocchi, Gino Roberto Corazza.   

Abstract

Bloating, abdominal distention, and flatulence represent very frequent complaints in functional disorders but their pathophysiology and treatment are largely unknown. Patients frequently associate these symptoms with excessive intestinal gas and the reduction of gas production may represent an effective strategy. The aim was to evaluate the effect of alpha-galactosidase administration, in a randomized double-blind placebo-controlled protocol, on intestinal gas production and gas-related symptoms after a challenge test meal in healthy volunteers. Eight healthy volunteers ingested 300 or 1200 GalU of alpha-galactosidase or placebo during a test meal containing 420 g of cooked beans. Breath hydrogen excretion and occurrence of bloating, abdominal pain, discomfort, flatulence, and diarrhea were measured for 8 hr. The administration of 1200 GalU of alpha-galactosidase induced a significant reduction of both breath hydrogen excretion and severity of flatulence. A reduction in severity was apparent for all considered symptoms, but both 300 and 1200 GalU induced a significant reduction in the total symptom score. Alpha-galactosidase reduced gas production following a meal rich in fermentable carbohydrates and may be helpful in patients with gas-related symptoms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17151807     DOI: 10.1007/s10620-006-9296-9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  37 in total

1.  Accelerated transit of intestinal gas with simethicone.

Authors:  I E Danhof; J J Stavola
Journal:  Obstet Gynecol       Date:  1974-07       Impact factor: 7.661

2.  Time-course of cigarette smoke contamination of clinical hydrogen breath-analysis tests.

Authors:  A Rosenthal; N W Solomons
Journal:  Clin Chem       Date:  1983-11       Impact factor: 8.327

3.  Effects of orally administered activated charcoal on intestinal gas.

Authors:  R G Hall; H Thompson; A Strother
Journal:  Am J Gastroenterol       Date:  1981-03       Impact factor: 10.864

4.  Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome.

Authors:  S Nobaek; M L Johansson; G Molin; S Ahrné; B Jeppsson
Journal:  Am J Gastroenterol       Date:  2000-05       Impact factor: 10.864

5.  Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease.

Authors:  F Castiglione; A Rispo; E Di Girolamo; A Cozzolino; F Manguso; R Grassia; G Mazzacca
Journal:  Aliment Pharmacol Ther       Date:  2003-12       Impact factor: 8.171

6.  Tolerance for rectosigmoid distention in irritable bowel syndrome.

Authors:  W E Whitehead; B Holtkotter; P Enck; R Hoelzl; K D Holmes; J Anthony; H S Shabsin; M M Schuster
Journal:  Gastroenterology       Date:  1990-05       Impact factor: 22.682

7.  Functional abdominal pain: further evidence that whole gut is affected.

Authors:  K J Moriarty; A M Dawson
Journal:  Br Med J (Clin Res Ed)       Date:  1982-06-05

Review 8.  Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria.

Authors:  J C Gillis; R N Brogden
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546

9.  Effects of beano on the tolerability and pharmacodynamics of acarbose.

Authors:  J T Lettieri; B Dain
Journal:  Clin Ther       Date:  1998 May-Jun       Impact factor: 3.393

10.  Activated charcoal: in vivo and in vitro studies of effect on gas formation.

Authors:  T Potter; C Ellis; M Levitt
Journal:  Gastroenterology       Date:  1985-03       Impact factor: 22.682

View more
  12 in total

1.  Structural analysis of Saccharomyces cerevisiae alpha-galactosidase and its complexes with natural substrates reveals new insights into substrate specificity of GH27 glycosidases.

Authors:  Rafael Fernández-Leiro; Angel Pereira-Rodríguez; M Esperanza Cerdán; Manuel Becerra; Juliana Sanz-Aparicio
Journal:  J Biol Chem       Date:  2010-06-30       Impact factor: 5.157

Review 2.  Improving the stability and activity of oral therapeutic enzymes-recent advances and perspectives.

Authors:  Gregor Fuhrmann; Jean-Christophe Leroux
Journal:  Pharm Res       Date:  2013-11-02       Impact factor: 4.200

3.  Increasing Symptoms in Irritable Bowel Symptoms With Ingestion of Galacto-Oligosaccharides Are Mitigated by α-Galactosidase Treatment.

Authors:  C J Tuck; K M Taylor; P R Gibson; J S Barrett; J G Muir
Journal:  Am J Gastroenterol       Date:  2017-08-15       Impact factor: 10.864

4.  Distinguishing the differences in β-glycosylceramidase folds, dynamics, and actions informs therapeutic uses.

Authors:  Fredj Ben Bdira; Marta Artola; Herman S Overkleeft; Marcellus Ubbink; Johannes M F G Aerts
Journal:  J Lipid Res       Date:  2018-10-02       Impact factor: 5.922

5.  Alpha-galactosidase versus active charcoal for improving sonographic visualization of abdominal organs in patients with excessive intestinal gas.

Authors:  G Maconi; E Bolzacchini; E Radice; M Marzocchi; M Badini
Journal:  J Ultrasound       Date:  2012-05-17

6.  Perceptions of flatulence from bean consumption among adults in 3 feeding studies.

Authors:  Donna M Winham; Andrea M Hutchins
Journal:  Nutr J       Date:  2011-11-21       Impact factor: 3.271

7.  A pilot trial on subjects with lactose and/or oligosaccharides intolerance treated with a fixed mixture of pure and enteric-coated α- and β-galactosidase.

Authors:  Francesco Di Pierro; Alexander Bertuccioli; Eleonora Marini; Leandro Ivaldi
Journal:  Clin Exp Gastroenterol       Date:  2015-02-19

Review 8.  Post-Prostatectomy Image-Guided Radiotherapy: The Invisible Target Concept.

Authors:  Florent Vilotte; Mickael Antoine; Maxime Bobin; Igor Latorzeff; Stéphane Supiot; Pierre Richaud; Laurence Thomas; Nicolas Leduc; Stephane Guérif; Jone Iriondo-Alberdi; Renaud de Crevoisier; Paul Sargos
Journal:  Front Oncol       Date:  2017-03-09       Impact factor: 6.244

9.  Efficacy and tolerability of α-galactosidase in treating gas-related symptoms in children: a randomized, double-blind, placebo controlled trial.

Authors:  Giovanni Di Nardo; Salvatore Oliva; Federica Ferrari; Saverio Mallardo; Giovanni Barbara; Cesare Cremon; Marina Aloi; Salvatore Cucchiara
Journal:  BMC Gastroenterol       Date:  2013-09-24       Impact factor: 3.067

10.  Use of the Biphasic (13)C-Sucrose/Glucose Breath Test to Assess Sucrose Maldigestion in Adults with Functional Bowel Disorders.

Authors:  Antone R Opekun; Albert M Balesh; Harold T Shelby
Journal:  Biomed Res Int       Date:  2016-08-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.